BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carr BI, Kanke F, Wise M, Satomura S. Clinical Evaluation of Lens Culinaris Agglutinin-Reactive α-Fetoprotein and Des-γ-Carboxy Prothrombin in Histologically Proven Hepatocellular Carcinoma in the United States. Dig Dis Sci 2007;52:776-82. [DOI: 10.1007/s10620-006-9541-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
2 Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol. 2012;39:434-439. [PMID: 22846860 DOI: 10.1053/j.seminoncol.2012.05.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
3 Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51:344-353. [PMID: 26340708 DOI: 10.3109/00365521.2015.1082190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
4 Zhu R, Yang J, Xu L, Dai W, Wang F, Shen M, Zhang Y, Zhang H, Chen K, Cheng P. Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis. Gastroenterol Res Pract. 2014;2014:529314. [PMID: 25165471 DOI: 10.1155/2014/529314] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
5 Owen WE, Roberts RF, Roberts WL. Performance characteristics of the LiBASys® des-gamma-carboxy prothrombin assay. Clinica Chimica Acta 2008;389:183-5. [DOI: 10.1016/j.cca.2007.11.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016; 22(12): 3325-3334 [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
7 Li GJ, Chen QY, Harrison TJ, Wang XY, Hu LP, Yang QL, Li KW, Fang ZL. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study. Cancer Biomark 2017;18:241-8. [PMID: 28085009 DOI: 10.3233/CBM-160131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Fatima S, Luk JM, Poon RT, Lee NP. Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert Rev Mol Diagn 2014;14:535-48. [PMID: 24809435 DOI: 10.1586/14737159.2014.915747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
9 Kogiso T, Sagawa T, Kotera Y, Egawa H, Yamamoto M, Tokushige K. Elevated α-Fetoprotein in the Absence of Carcinoma Caused by Relapse of Hepatitis C Viral Infection after Liver Transplantation. ACG Case Rep J 2018;5:e103. [PMID: 30643846 DOI: 10.14309/crj.2018.103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2009;7:104-113. [PMID: 18849011 DOI: 10.1016/j.cgh.2008.08.041] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
11 Sherman M. The resurrection of alphafetoprotein. J Hepatol. 2010;52:939-940. [PMID: 20395007 DOI: 10.1016/j.jhep.2010.02.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
12 Song BG, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Kim JM, Joh JW, Choi GS. Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. Transplant Proc 2020;52:881-8. [PMID: 32115240 DOI: 10.1016/j.transproceed.2020.01.037] [Reference Citation Analysis]
13 Riaz A, Salem R. Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. J Vasc Interv Radiol 2019;30:1893-4. [PMID: 31757337 DOI: 10.1016/j.jvir.2019.09.003] [Reference Citation Analysis]
14 Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-10583 [PMID: 26457017 DOI: 10.3748/wjg.v21.i37.10573] [Cited by in CrossRef: 188] [Cited by in F6Publishing: 182] [Article Influence: 26.9] [Reference Citation Analysis]
15 Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012;2012:859076. [PMID: 22655201 DOI: 10.1155/2012/859076] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
16 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
18 Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259-1266. [PMID: 18699979 DOI: 10.1111/j.1440-1746.2008.05487.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
19 Akbulut S, Koc C. Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation? J Gastrointest Cancer 2020;51:1107-13. [PMID: 32857265 DOI: 10.1007/s12029-020-00482-0] [Reference Citation Analysis]
20 Kawaguchi T, Ide T, Koga H, Kondo R, Miyajima I, Arinaga-Hino T, Kuwahara R, Amano K, Niizeki T, Nakano M, Kuromatsu R, Torimura T. Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C. Clin J Gastroenterol 2018;11:69-74. [PMID: 29082453 DOI: 10.1007/s12328-017-0789-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
21 Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, Konishi M, Takahashi S, Gotohda N, Suto K, Yoshida T, Nakatsura T. Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncol Lett 2020;19:2657-66. [PMID: 32218816 DOI: 10.3892/ol.2020.11371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 De J, Shen Y, Qin J, Feng L, Wang Y, Yang L. A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma. Medicine (Baltimore). 2016;95:e3448. [PMID: 27124038 DOI: 10.1097/md.0000000000003448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1541-1548. [PMID: 18422961 DOI: 10.1111/j.1440-1746.2008.05395.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 7.3] [Reference Citation Analysis]
24 Uygun Ilikhan S, Bilici M, Sahin H, Demir Akca AS, Can M, Oz II, Guven B, Buyukuysal MC, Ustundag Y. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World J Gastroenterol 2015; 21(22): 6999-7007 [PMID: 26078578 DOI: 10.3748/wjg.v21.i22.6999] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
25 El Fayoumie M, Abdelhady M, Gawish A, Hantour U, Abdelkhaleek I, Abdelraheem M, Alsawak A, Alwassief A, Elbahrawy A. Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. Gastrointest Tumors 2020;7:50-60. [PMID: 32399465 DOI: 10.1159/000505326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
27 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Masuda T, Miyoshi E. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clin Chem Lab Med 2011;49:959-66. [PMID: 21428856 DOI: 10.1515/CCLM.2011.152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
29 Wu W, Yao D, Qiu L, Gu X, Wu X. Quantitative analysis of hepatoma-specific α-fetoprotein (HS-AFP) by a new mini-column affinity chromatography and its clinical value in diagnosis of hepatocellular carcinoma. Chin -Ger J Clin Oncol 2008;7:131-4. [DOI: 10.1007/s10330-007-0167-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Mori Y, Tamai H, Shingaki N, Moribata K, Shiraki T, Deguchi H, Ueda K, Enomoto S, Magari H, Inoue I. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. Hepatol Int. 2009;3:509-515. [PMID: 19669252 DOI: 10.1007/s12072-009-9131-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
31 Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795-2804. [PMID: 19669841 DOI: 10.1245/s10434-009-0618-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
32 Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, Sawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget 2017;8:37835-44. [PMID: 28035063 DOI: 10.18632/oncotarget.14271] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
33 Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:56-60. [PMID: 22212937 DOI: 10.1159/000333261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhang JW, Peng C, Ye YS, Li W. Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report. World J Gastrointest Surg 2020; 12(12): 549-554 [PMID: 33437405 DOI: 10.4240/wjgs.v12.i12.549] [Reference Citation Analysis]
35 She WH, Chan ACY, Ma KW, Dai WC, Chok KSH, Cheung TT, Lo CM. Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma. Ann Transl Med 2021;9:919. [PMID: 34350234 DOI: 10.21037/atm-20-7611] [Reference Citation Analysis]
36 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
37 Dengler M, Staufer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, Kumada T, Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget 2017;8:46234-48. [PMID: 28526812 DOI: 10.18632/oncotarget.17598] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
38 Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 2015;137:385-394. [PMID: 25529751 DOI: 10.1002/ijc.29394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
39 Yu R, Xiang X, Tan Z, Zhou Y, Wang H, Deng G. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep 2016;6:35050. [PMID: 27731353 DOI: 10.1038/srep35050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
40 Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
41 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
42 Saito S, Ojima H, Ichikawa H, Hirohashi S, Kondo T. Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci 2008;99:2402-9. [PMID: 19038010 DOI: 10.1111/j.1349-7006.2008.00973.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
43 Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425:212-220. [PMID: 23954771 DOI: 10.1016/j.cca.2013.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
44 Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol. 2010;52:614-615. [PMID: 20185193 DOI: 10.1016/j.jhep.2009.11.026] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
45 Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 2012;12:e6122. [PMID: 23162601 DOI: 10.5812/hepatmon.6122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
46 Cabrera R, Fitian AI, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Liu C, Nelson DR. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncol Lett. 2012;4:840-846. [PMID: 23205111 DOI: 10.3892/ol.2012.826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
47 Carr BI, Guerra V. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Dig Dis Sci 2016;61:937-47. [PMID: 26576554 DOI: 10.1007/s10620-015-3922-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
48 Carr BI, Wang Z, Wang M, Wei G. Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. Dig Dis Sci 2011;56:1876-83. [PMID: 21188521 DOI: 10.1007/s10620-010-1521-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
49 Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107:64-74. [PMID: 21931376 DOI: 10.1038/ajg.2011.312] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 6.7] [Reference Citation Analysis]
50 Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. [PMID: 23738605 DOI: 10.1186/2046-4053-2-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
51 Azizi AA, Hadjinicolaou AV, Goncalves C, Duckworth A, Basu B. Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. Front Oncol 2020;10:570958. [PMID: 33102226 DOI: 10.3389/fonc.2020.570958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
53 Li B, Li B, Guo T, Sun Z, Li X, Li X, Chen L, Zhao J, Mao Y. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget 2017;8:80521-30. [PMID: 29113322 DOI: 10.18632/oncotarget.19298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
54 Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation: Monitoring Patients with Hepatocellular Carcinoma. Liver Transpl 2011;17:S117-27. [DOI: 10.1002/lt.22334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
55 Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, Yu YL. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2014;9:e99959. [PMID: 24927126 DOI: 10.1371/journal.pone.0099959] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
56 Na K, Jeong SK, Lee MJ, Cho SY, Kim SA, Lee MJ, Song SY, Kim H, Kim KS, Lee HW. Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients. Int J Cancer. 2013;133:408-415. [PMID: 23319432 DOI: 10.1002/ijc.28020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
57 Falahi S, Rafiee-Pour HA, Zarejousheghani M, Rahimi P, Joseph Y. Non-Coding RNA-Based Biosensors for Early Detection of Liver Cancer. Biomedicines 2021;9:964. [PMID: 34440168 DOI: 10.3390/biomedicines9080964] [Reference Citation Analysis]
58 Sherman M. Surveillance for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:783-93. [DOI: 10.1016/j.bpg.2014.08.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
59 Zhao Y, Li Y, Liu W, Xing S, Wang D, Chen J, Sun L, Mu J, Liu W, Xing B, Sun W, He F. Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics. Journal of Proteomics 2020;225:103780. [DOI: 10.1016/j.jprot.2020.103780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
60 Teng M, Pirrie S, Ward DG, Assi LK, Hughes RG, Stocken D, Johnson PJ. Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. Br J Cancer. 2014;110:2277-2282. [PMID: 24603305 DOI: 10.1038/bjc.2014.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
61 Hann HW, Jain S, Park G, Steffen JD, Song W, Su YH. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Res 2017;3:105-11. [PMID: 28795155 DOI: 10.20517/2394-5079.2017.15] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
62 Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang X, Wang M, Wen D, Zhu Y, Qin X. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One 2014;9:e85308. [PMID: 24416385 DOI: 10.1371/journal.pone.0085308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
63 Amarapurkar D, Han K, Chan HL, Ueno Y; The Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology 2009;24:955-61. [DOI: 10.1111/j.1440-1746.2009.05805.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
64 Ali R, Yang Y, Antkowiak M, Gabr A, Mora R, Abouchaleh N, Al Asadi A, Kulik L, Ganger D, Abecassis M, Kataraya N, Mulcahy M, Benson A, Mahalingam D, Thornburg B, Mouli S, Lewandowski RJ, Salem R, Riaz A. Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. Cardiovasc Intervent Radiol 2019;42:700-11. [DOI: 10.1007/s00270-019-02191-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
65 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16(4): 418-424 [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 110] [Article Influence: 9.3] [Reference Citation Analysis]
66 Xing H, Yan C, Cheng L, Wang N, Dai S, Yuan J, Lu W, Wang Z, Han J, Zheng Y, Yang T. Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. Tumor Biol 2016;37:15447-56. [DOI: 10.1007/s13277-016-5443-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
67 El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4:5-10. [PMID: 21317990 DOI: 10.1177/1756283x10385964] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
68 Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2010;4:396-405. [PMID: 20305756 DOI: 10.1007/s12072-009-9157-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
69 Ayoub WS, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. [PMID: 31523283 DOI: 10.1177/1758835919869120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
70 Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH, Moser CD, Oseini AM, Umeda N, Venkatesh S, Harnois DM, Charlton MR, Yamada H, Satomura S, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21:599-606. [PMID: 25789635 DOI: 10.1002/lt.24117] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 8.7] [Reference Citation Analysis]
71 Hakamada K, Kimura N, Miura T, Morohashi H, Ishido K, Nara M, Toyoki Y, Narumi S, Sasaki M. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 2008; 14(9): 1370-1377 [PMID: 18322950 DOI: 10.3748/wjg.14.1370] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
72 Omran MM, Emran TM, Farid K, Eltaweel FM, Omar MA, Bazeed FB. An Easy and Useful Noninvasive Score Based on α-1-acid Glycoprotein and C-Reactive Protein for Diagnosis of Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection. J Immunoassay Immunochem 2016;37:273-88. [PMID: 26685049 DOI: 10.1080/15321819.2015.1132229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
73 Tang X, Li H, Yan L, Zhou L, Chen E, Liu M, Zhang D, Tang H. Diagnostic value of PIVKA-II in detecting hepatocellular carcinoma. Future Virology 2017;12:259-67. [DOI: 10.2217/fvl-2017-0017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
74 Nakamura Y, Mizuguchi T, Kawamoto M, Meguro M, Harada K, Ota S, Hirata K. Cluster analysis of indicators of liver functional and preoperative low branched-chain amino acid tyrosine ration indicate a high risk of early recurrence in analysis of 165 hepatocellular carcinoma patients after initial hepatectomy. Surgery. 2011;150:250-262. [PMID: 21801962 DOI: 10.1016/j.surg.2011.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
75 Fu CL, Pan B, Pan JH, Gan MF. Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma. Oncotarget 2017;8:33037-46. [PMID: 28380433 DOI: 10.18632/oncotarget.16521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
76 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
77 Conti F, Dall'Agata M, Gramenzi A, Biselli M. Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med 2015;9:1343-51. [PMID: 26580585 DOI: 10.2217/bmm.15.100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
78 Fu X, Li X, Han D, Yang W, Liu C, Fan L, Ding S, Ma Y. Ultrasensitive electrochemical biosensor for des-gamma-carboxy prothrombin analysis based on core-shell Pd@PtCu-alloy loaded on WS2 nanosheet. Journal of Electroanalytical Chemistry 2021;888:115213. [DOI: 10.1016/j.jelechem.2021.115213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF, Tsai CN. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19 Suppl 3:S455-S463. [PMID: 21822558 DOI: 10.1245/s10434-011-1946-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
80 Chon YE, Choi GH, Lee MH, Kim SU, Kim do Y, Ahn SH, Kim KS, Choi JS, Han KH, Chon CY. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer. 2012;131:2332-2341. [PMID: 22362471 DOI: 10.1002/ijc.27507] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
81 Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China. J Clin Lab Anal 2021;35:e24013. [PMID: 34590755 DOI: 10.1002/jcla.24013] [Reference Citation Analysis]
82 Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol 2013; 19(11): 1811-1819 [PMID: 23555170 DOI: 10.3748/wjg.v19.i11.1811] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 68] [Article Influence: 7.4] [Reference Citation Analysis]